Идёт набор NCT05088395

Analysis of Circulating Tumor mArkers in Blood 4 - ALCINA 4

Без фазы С лечением Cancer

Ориентир для пациента и семьи

Простыми словами

Автоматическая сводка по структурированным данным реестра. Она помогает сориентироваться, но не заменяет официальный протокол или оценку врача.

Что изучают: В протоколе указаны: Blood sample, Biopsy.
Кому может быть актуально: Состояния в реестре: Cancer. Базовые параметры: от 18 лет · Все.
Что важно проверить: Возраст, диагноз и пол — только базовые ориентиры. Предыдущее лечение, анализы и другие обязательные условия указаны ниже в критериях участия.
Где проводится: Франция
Следующий шаг: Сохраните исследование, покажите его лечащему врачу и уточните актуальный статус у исследовательского центра. Расходы, документы и поездка →

Не всё понятно в терминах? Прочитайте наш гид для пациентов →

Обзор

Multi-cohort exploratory prospective study. Participation in the ALCINA 4 study does not change the standard management of the patient, including the treatments administered. A sampling schedule will be set up for each cohort. Depending on the clinical context studied and the biomarkers studied and/or sought, the timing of blood samples will vary between cohorts. There may be up to 4 samples (or more) taken per patient for up to 18, 24 or 36 months. If a specific tumor sample is required, it will be collected only once during the study.

Подробное описание

The ALCINA 4 study is a prospective biological cohort study based on the analysis of circulating tumour biomarkers obtained by blood sampling, with comparison - if necessary - with tumour material obtained by biopsy.

Circulating tumour biomarkers in blood have been the subject of much research for several decades, leading to the development in the 1980s of serum protein markers still in use today (CA15.3, ACE, CA125...). In the last decade, research has focused on circulating tumour cells (CTCs), circulating endothelial cells (CECs) and more recently on the detection of circulating tumour DNA (ctDNA) and exosomes (or microvesicles). While ctDNA seems to have a very promising future, other circulating elements such as microRNA are also part of what can/will be studied from a simple blood sample. Broadly speaking, the potential clinical interests of these circulating biomarkers are :

* diagnostic (diagnosis of cancer, or especially diagnosis of genetic mutations present in a known cancer) * prognostic (to adapt the intensity of treatment to the expected outcome of the patient) * predictive of the efficacy of targeted therapies (according to the mutational profile of the cancer) * to study mechanisms of resistance during treatment . The multiplicity of these potential blood biomarkers is matched by a large number of detection techniques, for example for CTCs or ctDNA.

The major new challenge in research on circulating biomarkers is to replace molecular analyses on tumour tissue obtained by biopsy (e.g. the search for somatic cancer mutations) by a simple blood sample ("liquid biopsy"). This objective, which is technologically possible in the very short term and particularly interesting - both medically (for patients) and economically - requires the comparison of data from blood markers with those from tumour tissue samples. Furthermore, there is an important trend to combine several levels of analysis together (e.g. ctDNA and serum protein markers) to refine the performance of blood tests.

Вмешательства

Другое Blood sample
Depending on the clinical context studied and the biomarkers studied and/or sought, the timing of blood samples will vary between cohorts. There may be up to 4 samples (or more) taken per patient for up to 18, 24 or 36 months according to the cohorts.
Другое Biopsy
If a specific tumor sample is required, it will be collected only once during the study

Первичные конечные точки

Detection rate of circulating biomarkers in cohort 1 [Срок оценки: Baseline]
Detection rate of circulating biomarkers in cohort 2 [Срок оценки: Baseline]
Detection rate of circulating biomarkers in cohort 2 [Срок оценки: Before treatment]
Detection rate of circulating biomarkers in cohort 2 [Срок оценки: At 3 weeks of treatment]
Detection rate of circulating biomarkers in cohort 2 [Срок оценки: At 9 weeks of treatment]
Detection rate of circulating biomarkers in cohort 2 [Срок оценки: At disease progression]
Detection rate of circulating biomarkers in cohort 1 [Срок оценки: Before surgery]
Detection rate of circulating biomarkers in cohort 1 [Срок оценки: After surgery (from 3 to 5 weeks)]
Detection rate of circulating biomarkers in cohort 1 [Срок оценки: After surgery (from 2 to 3 months)]
Detection rate of circulating biomarkers in cohort 3 [Срок оценки: Baseline]

Критерии участия

Критерии включения

Patient treated for cancer at one of the participating center
18 years old or higher
Signed informed consent form
Patient not deprived of their liberty or under guardianship (including temporary guardianship)
Patient covered by social security scheme
Patient with no compliance issue (related to geographical, social or psychological reasons) for study follow up
Other additional criteria will be defined (defining tumor type and clinical setting), by cohort

If a biopsy tumor sample is to be taken:

Tumor considered as accessible by biopsy (at the investigator's discretion).
Normal blood coagulation tests (if applicable, and in case of a non-superficial tumor lesion).
No anticoagulant or antiaggregant treatment for the biopsy.